MedTrace Logo

SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors

NCT06562647 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-02-13

No results posted yet for this study

Summary

Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.

Conditions

Interventions

DRUG

SY001

PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages

Sponsors & Collaborators

  • Cell Origin Biotech (Hangzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-12
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06562647 on ClinicalTrials.gov